IXUS or SPGM: Which is the Better International All-Cap ETF?

IXUS has the lower expense ratio at 0.07% versus 0.09% for SPGM and a higher dividend yield of 3.0% versus 1.8%, while SPGM has outperformed over 1 year (39.7% vs 37.4%) and 5 years ($1,674 vs $1,481 on $1,000). SPGM is larger in U.S.-heavy global exposure with $1.5B in AUM and a 25% technology tilt, whereas IXUS has $56.0B in assets, broader non-U.S. diversification, and a 23% financials weight. The piece is largely comparative and informational, with limited immediate market impact.

Analysis

The real divergence is not “international vs global,” but factor exposure: SPGM is effectively a U.S. mega-cap growth carry trade wrapped in an ETF, while IXUS is a cleaner claim on the rest of the world, especially financials, industrials, and Asia hardware. That matters because the recent outperformance gap is likely less about better index construction and more about a regime where U.S. tech momentum and AI capex have dominated returns; if that leadership broadens or stalls, the relative gap can compress quickly.

IXUS’s higher yield and lower fee improve expected return in flat-to-modestly up markets, but its bigger hidden advantage is diversification away from the most crowded U.S. large-cap names. The risk is that its heavier financials and emerging-market exposure make it more sensitive to dollar strength, curve shape, and China/Taiwan headline risk; those factors can dominate returns over a 3-12 month horizon even if fundamentals are stable. Conversely, SPGM’s apparent safety is partly concentration risk in the same handful of tech winners that have already driven index-level returns.

A key second-order effect is supply-chain and geography leakage: IXUS gives more direct exposure to semiconductor manufacturing and capital equipment outside the U.S., which can outperform if AI spending diffuses from U.S. platforms into hardware and upstream suppliers. TSM and ASML are the clearest beneficiaries of that path, while AAPL/MSFT/NVDA benefit if global growth holds but are more vulnerable to multiple compression because they are embedded in SPGM’s already crowded U.S. sleeve. The market is probably underpricing how much of “global” exposure in SPGM is still just one-country beta with a tech wrapper.

The contrarian take is that IXUS may be less of a pure defensive diversifier than it looks: if rates stay elevated and the dollar firms, its yield pickup won’t fully offset valuation pressure in banks, cyclicals, and EM-linked exporters. In that scenario, the recent relative strength of SPGM could persist longer than headline fee/yield comparisons suggest, but the payoff is increasingly dependent on continued U.S. tech exceptionalism rather than broad market breadth.

Key Decisions for Investors

• Long IXUS / short SPGM in a 3-6 month relative-value trade if you expect U.S. tech leadership to mean-revert; target 3-5% relative outperformance for IXUS, but stop if NVDA/MSFT continue to accelerate on AI capex.
• For core allocations, rotate new international capital into IXUS rather than SPGM over the next 1-2 quarters: you’re paying 2 bps less and getting materially better yield/dollar diversification, with the tradeoff of higher EM/financials sensitivity.
• Pair TSM/ASML vs AAPL/MSFT as a second-order beneficiary trade over 6-12 months: if global AI infrastructure spending broadens beyond U.S. software/platforms, the non-U.S. semicap stack should re-rate faster than the crowded mega-cap software complex.
• Avoid using SPGM as a true hedge against U.S. equity concentration; if your intent is diversification, it should be paired with non-U.S. exposure or alternatives, not mistaken for a neutral global basket.
• Watch the DXY and U.S. 10Y move over the next 1-3 months: a rising dollar/rates combo is the cleanest signal to fade IXUS beta and wait for a better entry; a softer dollar improves the relative setup materially.